kerostx.com - KROS Profit before deduction of interest, taxes, depreciation and amortization

Public company logo of Keros Therapeutics, Inc. (KROS)

Keros Therapeutics (KROS) minimizes risks through the diversification of its bone and blood treatment programs. The absolute operating profit metric on GURU.Markets reflects cash flow dynamics, where the value is maintained at 0.00. The strategy is based on pricing power within the TGF-beta protein niche, while experienced management ensures the steady development of clinical trials for rare hematological pathologies.

kerostx.com (KROS) Operating profit EBITDA: for the period 11/23/2025 - 11/15/2026

Summary analytical data breakdowns for Keros Therapeutics, Inc. (KROS)

- stock value and consensus price forecast:
Summary company analytics:Keros Therapeutics
Brand item of kerostx.com

Investors are seeking a fundamental anchor in the stability of the issuer's cash flows. For the biotech company Keros Therapeutics (KROS), which is developing drugs for myelofibrosis and hypertension, resource autonomy is critical. This basic operating result before depreciation measures profit before deducting non-cash expenses and interest. The trend of this metric reflects the company's ability to fund clinical trials without external loans. The stability of this metric confirms the asset's investment reliability ahead of a potential M&A.

Who Keros Therapeutics competes with

Operating income before deduction of amortization Vertex (VRTX)|ALNY: Operating profit before deduction of amortization|Profit before deduction of interest, taxes, depreciation and amortization INSM|UTHR: Operating profit EBITDA|Profit before interest, taxes and amortization BioMarin Pharma (BMRN)|BBIO (BridgeBio) - Operating profit EBITDA|BGM: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization COGT (Cogent Biosciences, Inc.)|XERS (Xeris Biopharma Holdings, Inc.) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Arcturus Therapeutics Holdings Inc. ARCT|ETON (Eton Pharma) - Profit before deduction of interest, taxes, depreciation and amortization|Kamada Ltd. - Operating profit EBITDA|Income before deduction of interest, taxes and amortization FULC (Fulcrum Therapeutics)|ABEO: Operating profit EBITDA|Mereo BioPharma Group PLC (MREO) - Operating profit EBITDA|Profit before payment of interest, taxes and amortization Protalix BioTherapeutics, Inc|PLRX: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Applied Therapeutics Inc. (APLT)|Operating profit before deduction of amortization Rein Therapeutics Inc RNTX|Operating profit EBITDA GELS (Gelteq Ltd)|Operating profit EBITDA Aytu Therapeutics AYTU|Chemomab Therapeutics Ltd. - Operating profit EBITDA|Operating income before deduction of amortization SRx Health Solutions SRXH|polyrizon-biotech.com (PLRZ) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization Aeterna Zentaris (AEZS)|CYTH (Cyclo Therapeutics Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Inozyme Pharma INZY|Operating profit EBITDA RPHM|Operating profit before deduction of amortization Aeterna Zentaris CSCI